When Mendelsohn joined MD Anderson, he had an international reputation for his research on how the binding of growth factors to cell-surface receptors regulates cell functions.
He and Gordon Sato and their collaborators in California produced monoclonal antibody 225, which inhibits human cancer cell proliferation by blocking the signaling pathways that are activated by epidermal growth factor receptors.